Inactive Instrument

News Neuropathix, Inc.

Equities

NPTX

US64132Q1094

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-23	AQ
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Neuropathix : OTC Certification - Neuropathix, Inc. - FYE 2021	22-04-25	PU
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
NEUROPATHIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	22-04-15	AQ
Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	22-03-25	AQ
Neuropathix, Inc. announced that it has received $0.15 million in funding	22-03-20	CI
NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21-11-12	AQ
Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
NEUROPATHIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	21-09-28	AQ
Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	21-08-12	CI
NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21-08-06	AQ
Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-06	CI
Neuropathix : Neuropathix, Inc.	21-07-20	AQ
NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21-05-13	AQ
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology	21-05-06	GL
NEUROPATHIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	21-03-30	AQ
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Neuropathix, Inc.

Equities

NPTX

US64132Q1094

Summary

Filters